Home > Insider Trading > Filing (0000899243-23-004412)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534120	Avalo Therapeutics Inc.	AVTX	Pharmaceutical Preparations (2834)	450705648

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York NY 10022	No	No	Yes	No
1633584	Ltd. Fund Master Capital Armistice	510 Madison Avenue 7Th Floor New York NY 10022	No	No	Yes	No
1706140	Steven Boyd	510 Madison Avenue 7Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-02-03	334	$3.95	3,965,000	No	4	L	Indirect	See Footnote
Common Stock	Acquisiton	2023-02-07	450,000	$0.00	4,415,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	L	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant	Acquisiton	2023-02-07	450,000	$0.00	450,000	$5.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
450,000	2023-02-07	2024-02-07	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	34,370	Direct

Footnotes

This amount reflects the effect of the 1-for-12 reverse stock split.
The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Each share of common stock and accompanying warrant were purchased together for $3.98. The warrants are subject to a 4.99% beneficial ownership limitation on exercise.
These shares are directly owned by Mr. Boyd in his personal capacity.